Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human pancreatic ductal cells from non-diabetic donors function as non-professional antigen-presenting cells upon inflammatory cytokine exposure.

Diabetologia·2026
Same author

If Plan A Does Not Work: The CD47 Ectodomain as a Target for Immune Tolerance.

Cells·2026
Same author

Can Islet Transplantation Possibly Reduce Mortality in Type 1 Diabetes.

Cell transplantation·2025
Same author

CD47 is Required for Mesenchymal Progenitor Proliferation and Fracture Repair.

bioRxiv : the preprint server for biology·2024
Same author

The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era.

Cancer immunology, immunotherapy : CII·2023
Same author

Thrombospondin-1, CD47, and SIRPα display cell-specific molecular signatures in human islets and pancreata.

American journal of physiology. Endocrinology and metabolism·2023
Same journal

Correction to "[NSUN2 promotes colorectal cancer progression and increases lapatinib sensitivity by enhancing CUL4B/ErbB-STAT3 signalling in a non-m5C manner]".

Clinical and translational medicine·2026
Same journal

USP43-mediated deubiquitination of SLC7A11 protects against LPS-induced acute lung injury by inhibiting ferroptosis.

Clinical and translational medicine·2026
Same journal

Tumour-macrophage crosstalk initiated by NFIC/METTL3 negative feedback loop via exosomal miR-194-5p promotes NSCLC progression.

Clinical and translational medicine·2026
Same journal

α7nAChR agonist GTS-21 ameliorates sepsis-induced acute kidney injury via MEF2/PGC-1α/HO-1 axis in mice.

Clinical and translational medicine·2026
Same journal

A living biobank of sarcoma patient-derived cell cultures reveals multi-omic and functional insights that capture disease heterogeneity.

Clinical and translational medicine·2026
Same journal

Unveiling non-small cell lung cancer-specific circulating Treg subtype: A paradigm shift in single-cell immunology and its clinical implications.

Clinical and translational medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits
10:15

The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits

Published on: August 20, 2014

11.6K

Tolerating CD47.

Jeffrey S Isenberg1, Enrique Montero2

  • 1Department of Diabetes Complications & Metabolism, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope National Medical Center, Duarte, California, USA.

Clinical and Translational Medicine
|February 16, 2024
PubMed
Summary
This summary is machine-generated.

Cluster of differentiation 47 (CD47) is a cell surface protein with complex roles in cell interactions. Understanding its dual functions is key to developing new therapies for cancer and autoimmune diseases.

Keywords:
CD47SIRPαTSP1autoimmunitycancercheckpoint inhibitorimmunotherapy

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

4.6K

Related Experiment Videos

Last Updated: Jun 7, 2026

The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits
10:15

The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits

Published on: August 20, 2014

11.6K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

4.6K

Area of Science:

  • Immunology
  • Cell Biology
  • Drug Development

Background:

  • Cluster of differentiation 47 (CD47) is a cell surface protein involved in cell-cell interactions.
  • CD47 plays a role in immune responses and is a target for drug development.
  • Previous clinical trials of CD47-blocking antibodies have faced setbacks.

Purpose of the Study:

  • To explore the complex and seemingly conflicting roles of CD47.
  • To investigate the therapeutic potential of modulating CD47 activity.
  • To consider implications for autoimmune diseases and cancer.

Main Methods:

  • Review of existing literature on CD47.
  • Analysis of CD47's position as a junction for receptor-ligand interactions.
  • Consideration of signaling pathways influenced by CD47.

Main Results:

  • CD47 exhibits pleiotropic effects due to its extensive receptor-multiligand network.
  • On-target effects of CD47 modulation are often overlooked.
  • CD47's dual role as a connector of receptors and signaling pathways impacts various cell types.

Conclusions:

  • The clinical utility of CD47 modulation (both blocking and boosting) requires further investigation.
  • CD47's complex functions present both challenges and opportunities for therapeutic intervention.
  • Targeting CD47 may offer potential benefits for autoimmune diseases and cancer treatment.